Abstract

EMERGING TRENDS IN ANTICOAGULATION THERAPY

*Pathan Kamran Ayubkhan, Mr. Sunil Dongre, Dr. Ganesh S. Tolsarwad

Abstract

Anticoagulation therapy is the first line and drug of choice for both the treatment and prophylaxis of venous thromboembolism (deep vein thrombosis and/or pulmonary embolism). Anticoagulation drugs, ranging from different preparations of heparin, warfarin, and newer direct oral drugs such as rivaroxaban and dabigatran, work mainly by inhibiting important factors and enzymes in the coagulation cascade by preventing fibrin formation, platelet aggregation, and clot assembly With recurrent thrombosis and embolisms being a feared complication for many physicians treating such cases, anticoagulation is often extended beyond the initial three- to six-month acute phase after an incident of venous thromboembolism. For some groups of patients, anticoagulation needs to be offered indefinitely to decrease the risk of a recurrent thrombosis. However, this concomitantly increases obvious and dangerous adverse effects such as increased risk of hemorrhage, as the ability to clot is hindered. This tradeoff between recurrent venous thromboembolism and bleeding is what underscores the controversy of the clinical question.

Keywords: General introduction of Direct oral anticoagulants, Venous thromboembolism, Deep venous thrombosis, VTE, chemoprophylaxis, VTE extended therapy, Anticoagulation, Perioperative bridging G Therapy.